February 14, 2006
Posted by
Mark Reichel
/ 2:17 PM /
U.S. Patent No. 6,995,278 ("Antiangiogenic agents") issued on 2/7/06, providing the Rockville, Maryland, pharmaceutical company with even broader intellectual property protection on its lead cancer drug, Panzem(R) . Panzem is touted as a "next generation antimitotic cancer drug" that focuses on destroying cancerous tumors in more than one fashion. Several Phase I and II clinical trials are either ongoing or about to begin, with three trials to occur here in Indianapolis, Indiana.
EntreMed Press Release: LINK
U.S. Patent No. 6,995,278: LINK
EntreMed Press Release: LINK
U.S. Patent No. 6,995,278: LINK
0 comments:
Post a Comment